Close

Versartis (VSAR) Completes Phase 3 VELOCITY Trial Enrollment

August 22, 2016 8:33 AM EDT Send to a Friend
Versartis, Inc. (Nasdaq: VSAR) announced the completion of enrollment in the Phase 3 VELOCITY trial of somavaratan in pediatric GHD ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login